Sebesta C, Tiefengraber E, Kier P, Ruckser R, Habertheuer K H, Schmid A, Hinterberger W
Ludwig-Boltzmann-Institut für Stammzelltransplantation, Wien.
Wien Med Wochenschr. 1995;145(2-3):47-50.
Although adjuvant chemotherapy has made some progress in the treatment of colorectal cancer, chemotherapy of metastatic disease remains disappointing. Autologous bone marrow or stem cell transplantation following supralethal chemotherapy is presently not of major significance in tumors of the intestine. The registry of the EBMT (European Cooperative Group for Blood and Marrow Transplantation) contains at March 1993 a total of 2085 cases of autotransplants for solid tumors, of which only 19 were performed for disseminated gastrointestinal cancer (15 gastric, 4 colon). It remains to be shown, whether the presently poor results can be improved upon inclusion of lymphokine-activated killer cells (LAK-cells) by use of cytokine combinations or by the use of tumor infiltrating lymphocytes (TIL) post transplantation.
尽管辅助化疗在结直肠癌治疗方面取得了一些进展，但转移性疾病的化疗效果仍然令人失望。超致死量化疗后进行自体骨髓或干细胞移植目前在肠道肿瘤中并不具有重要意义。欧洲血液和骨髓移植合作组（EBMT）的登记资料显示，截至1993年3月，共有2085例实体瘤自体移植病例，其中仅有19例是针对播散性胃肠道癌（15例胃癌，4例结肠癌）进行的。目前尚不清楚，通过使用细胞因子组合纳入淋巴因子激活的杀伤细胞（LAK细胞）或移植后使用肿瘤浸润淋巴细胞（TIL）是否能改善目前较差的治疗结果。
